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The MRI image shows herniation of cerebellar tonsils in the
foramen magnum and syringomyelia of (C2-C5) (Figure 3).
Together, these features were consistent with the diagnosis of
Type 1 Arnold Chiari syndrome. So, the vanishing head of hu-
merus was due to bone resorption secondary to an advanced and
rather unusual neuropathic joint. Then, pursuing the diagnosis of
Type 1 Arnold Chiari syndrome in this patient was clearly,
worthwhile particularly. in presence of a coexisting DM which
is capable of producing neuropathic joint. Rheumatoid arthritis
on the other hand was also reported to cause Gorham’s disease,
though rarely.
Conclusion: The message derived from this report that in
some clinical instances the real cause of the disorder can be
overshadowed by another condition(s) that might lead to a
similar presentation.
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Objectives: To characterize the muscle health decline of older
adults over 1 year and its association with adverse conse-
quences over the 3 following years.
Methods: The SarcoPhAge cohort follows up 534 older adults
to assess health consequences of sarcopenia. Subjects are seen
annually and an assessment of muscle mass (DXA), muscle
strength (handheld dynamometer) and physical performance
(4-m gait speed) are performed. Outcomes are collected either
during annual follow-up visits or by phone. Individual relevant
decline of muscle mass, muscle strength and gait speed between
baseline and the 1-year follow-up was evaluated using the
Edwards-Nunnally index. The association between muscle de-
cline and occurrence of outcomes was tested using logistic re-
gressions. Missing data were handle using multiple imputations.
Results: 534 subjects were recruited (73.5±6.2 y, 60.5%
women) but during the first year, 7 deaths occurred.
Consequently, analyses were performed on 528 subjects.
The prevalence of a rapid muscle mass decline was 41.5%
(n=219). Subjects presenting a decline of muscle mass had
no difference of their demographic or clinical characteristics
compared to subjects without decline (all p > 0.05). The prev-
alence of a rapid decline of muscle strength was 47.3%
(n=149). Subjects presenting a decline in muscle strength
were more often women (21.2% of male vs. 66.0% of male,
p=0.02) and had a lower cognitive status (27.6 points vs. 28.1
points at the MMSE, p=0.02). A significant decline in gait
speed was observed in 28.2% (n=149) of the whole popula-
tion. Subjects presenting decline of physical function were
older (74.5 years vs. 73.0 y, p=0.01), had lower BMI and
cognitive status (25.8 vs. 26.8, p=0.03 and 27.5 points vs.
28.0 points at the MMSE, p=0.04). Over the 3 following
years, a rapid decline in muscle mass and strength did not
predict the occurrence of falls, fractures and hospitalisations.
A rapid decline in gait speed predicted the occurrence of self-
reported physical disabilities (adjusted OR=1.87[1.18-2.96])
as well as deaths (adjusted OR=2.36 [1.17-4.73]).
Conclusion: A significant proportion of the older population
showed a rapid decline in muscle health, associated with age,
sex, BMI and cognitive status. A rapid decline of gait speed
predicted the occurrence of 3-y death and disabilities,
highlighting the importance of an assessment of gait speed
in older subjects.
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Objectives: In June 2018, we published a manuscript showing
that sarcopenia, characterized by the EWGSOP definition (i.e.,
EWGSOP1), was associated with an increased risk of mortality
(doi: 10.1016/j.jamda.2018.06.004). In October 2018, the
EWGSOP proposed a new operational definition of sarcopenia
(i.e., EWGSOP2). We sought to compare the prevalence of
sarcopenia defined by EWGSOP1 and by EWGSOP2, and to
determine the major outcomes associated with each of these
definitions.
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Methods: We used data available from the SarcoPhAge (for
Sarcopenia and Physical Impairment with Advancing Age)
cohort. To characterize sarcopenia, 3 main assessments were
performed: the skeletal muscle mass index using DXA, the
muscle strength using hand-dynamometer and the physical
performance using SPPB test. According to EWGSOP1,
sarcopenia is defined as a low muscle mass (i.e., ≤5.5 kg/m2
for women, ≤7.26 kg/m2 for men) plus a low grip strength
(i.e., <20 kg for women, <30 kg for men) and/or low physical
performance (i.e., ≤8 points/12). According to EWGSOP2,
sarcopenia is characterized by a low grip strength (i.e.,
<16 kg 7 for women, <26 kg for men) plus a low muscle mass
(i.e., <6 kg/m2 for women, <7 kg/m2 for men). If low physical
performance ((i.e., ≤8 points/12) is also present, there is ‘se-
vere sarcopenia’. Outcomes were collected yearly during in-
terview or by phone call. Association between sarcopenia and
occurrence of outcomes was tested using Cox hazards model
or logistic regression with adjustment for covariates known to
potentially impact muscle health, including age, sex, BMI,
number of comorbidities, number of coprescriptions, nutri-
tional status, and cognitive status.
Results: 534 subjects were recruited (73.5±6.2 y, 60.5% fe-
male). After 3 y, 33 participants were lost to follow-up, so data
were available for 501 subjects. According to EWGSOP1, the
prevalence of sarcopenia reached 13.6% and, when using the
EWGSOP2, 7.4%. Sarcopenia, defined by EWGSOP1, was
associated with an increased risk of 3-year mortality
(HRadjusted=2.93 [1.17-7.35]). According to EWGSOP2, this
association was no longer significant (HRadjusted=2.74 [0.98-
7.65]), but remained in the same range as observed for
EWGSOP1. In the subgroup of subjects with severe
sarcopenia, we observed a higher occurrence of death
(HRadjusted=4.50 [1.56-12.98]) and institutionalization
(HRadjusted=5.07 [1.02-25.27]) than in non-sarcopenic
individuals.
Conclusion: The EWGSOP2 definition of sarcopenia appears
to decrease its prevalence due to changes in the algorithm and/
or the thresholds compared to EWGSOP1. Furthermore, the
proposed severity index, based on physical performance as-
sessment, seems to be a determinant of the occurrence of
deaths and institutionalizations.
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Objective: Sarcopenia and osteoporosis increase the risk of
falls, resulting in fragility fracture. The prevalence of
sarcopenia was found to be alarmingly high (73.6% in males
and 67.7% in females) in geriatric hip fracture patients [1].
Intervention program on sarcopenic hip fracture was set up
at our center.
Method: All patients age over or equal to 65 admitted to
Caritas Medical Centre with operatively treated hip frac-
tu r e and d iagnosed sa rcopen ia were inc luded .
Interventions include inpatient nursing education, dietary
advice, therapist assessment and structured 12-week geri-
atric day hospital (GDH) exercise program. Those not
eligible for GDH training were classified as control
group. Changes in relative skeletal muscle mass index
(RASM), muscle strength, functional scores were
measured.
Results: There were 9 intervention and 10 control pa-
tients. The mean age in intervention group was 81.8 and
control group was 77.0. Female to male ratio in interven-
tion group was 7:2 and control group was 8:2. All patients
were noted to have increment in RASM (intervention
0.316 mm/kg2, control 0.655 mm/kg2, p<0.05), knee ex-
tension of good limb (intervention 1.32 kg, control 0.92
kg, p<0.05) and injured limb (intervention 5.78 kg, con-
trol 3.49 kg, p<0.0.5). All patients have improvement in
functional scores (p<0.05). Between groups analysis
showed there was statistically significant improvement
in muscle strength of both good and injured limbs.
There was also statistically insignificant decrement in
RASM, MFAC and BI in intervention program group
compared with control group.
Conclusion:Generally, there were improvement in muscle
mass, muscle strength and functional recovery in all pa-
tients. There was apparent improvement in muscle
strength but reduction in muscle mass in intervention
group compared with control group. The result shows that
intervention program with exercise prescription in
sarcopenic hip fracture patient can improve the lower
limb muscle strength but not muscle mass. These patients
may be too frail to benefit from traditional exercise treat-
ment for sarcopenia. Hip fracture patients with sarcopenia
may represent a special group of sarcopenic individuals
that are resistant to traditional exercise treatment for
sarcopenia. Further studies are needed to investigate the
potential benefits of extension of rehabilitation training
program for this group of frail patients on sarcopenia
treatment.
Reference: 1. Ho AW et al. Hong Kong Med J 2016;22:23
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Objectives:Anorexia nervosa happens to be one of the threat-
ened psychological conditions which affect mostly teenagers.
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